Gilead to Topple GSK as the Top Player in the Anti-Infectives Drug Market in 2014.
Stringent, Yet Ill-Defined, Approval Standards Make it Difficult for Companies to Bring Hospital Antibiotics to Market, According to a New Report from Decision Resources WALTHAM, Mass., Nov. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues,...

Painkillers, anti-infectives gain.
Byline: Rupali Mukherjee NEW DELHI: Growing incidence of viral infections, and diseases such as Chikungunya this year have led to a huge spurt in the sales of pain-killers and anti-infectives during the monsoon months. Sales of pain killers (anti-rheumatic, non-steroidal) shot up to over 32% during the...

Anadys Pharmaceuticals Invites Investors to Listen to Webcast of Anti-Infectives Panel Discussion at RBC Capital Markets Healthcare Conference.
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will participate in a panel discussion entitled, "Anti-infectives: Bugs Beware" at the RBC Capital Markets Healthcare Conference on Thursday, December 14, 2006 at 11:00 a.m. EST (8:00 a.m. PST) at The Westin New York at Times...

Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis.
ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- Scientists at NanoBio Corp. and the University of Michigan have demonstrated in the laboratory that their novel topical nanoemulsion kills the highly resistant strains of bacteria that cause chronic illness and death among individuals with cystic fibrosis. The findings are...

PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy.
BRIDGEWATER, N.J., Feb. 11 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., today announced the availability of a lower-dose (75 mg) formulation of PREZISTA (darunavir) for pediatric patients with HIV. The announcement follows the FDA approval of PREZISTA, co-administered with ritonavir (PREZISTA/r) and with other...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan.
Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced that the two companies have...

DSM Anti-Infectives to launch restructuring measures.
DSM Anti-Infectives, the world's largest producer of penicillin and antibiotic products (including amoxicillins and cephalosporins), has announced a drastic package of measures, in accordance with the announcement made during the presentation of DSM's third-quarter results. The aim of the measures is to improve profitability in the short term and...

AMRAD TO DEMERGE ANTI-INFECTIVES BUSINESS.
Australian biotech Amrad will spin-out its advanced anti- infectives drug portfolio into a new corporate entity, Avexa Limited. The spin-out will be effected by a demerger to existing Amrad shareholders. Thus, Amrad shareholders will become entitled to shares comprising approximately 80% of the demerged company while Amrad...

Anti-infectives. (Drugs, Pregnancy, and Lactation).
This is my fourth and final installment on anti-infectives * Anthelmintics. All three agents in the benzimidazole class of the anthelmintics are rated pregnancy category C. In humans, their bioavailability is extremely low, but increases substantially when taken with fatty foods. There are few data...

Anti-infectives. (Drugs, Pregnancy, and Lactation).
I frequently get calls from physicians who have questions about the safety of different anti-infectives during pregnancy or breast-feeding. In this and future columns, I will review what is known about this large class of drugs when used in these two situations. * Penicillins. There is no...